Natural Product (NP) Details
General Information of the NP (ID: NP8829) | |||||
---|---|---|---|---|---|
Name |
Oroxylin A
|
||||
Synonyms |
Oroxylin; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one; 5,7-dihydroxy-6-methoxy-2-phenyl-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-6-methoxy-2-phenyl-; UNII-53K24Z586G; Baicalein 6-methyl ether;6-Methoxybaicalein; CHEBI:61668; 5,7-dihydroxy-6-methoxy-2-phenyl-4H-chromen-4-one; MFCD02259441; 53K24Z586G; Oroxylin-A; 6-Methoxybaicalein;; baicalein 6-methyl ether; Oroxylin?A; 5,7-dihydroxy-6-methoxyflavone; 5,7-Dihydroxy-6-methoxyflavone;; SCHEMBL431423; CHEMBL183513; DTXSID70197375; Oroxylin A, >=98% (HPLC); BCP31803; EX-A4028; HY-N0560; ZINC5998558; BDBM50430091; LMPK12111096; s9204; AKOS015903364; CCG-267292; CS-4948; AC-31960; AK168138; BS-16891; FT-0688332; O-160; Y0150; A14367; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one.; 5,7-Dihydroxy-6-methoxy-2-phenyl-chromen-4-one; Q3356627
Click to Show/Hide
|
||||
Species Origin | Oroxylum indicum ... | Click to Show/Hide | |||
Oroxylum indicum | |||||
Disease | Ovarian cancer [ICD-11: 2C73] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C16H12O5
|
||||
PubChem CID | |||||
Canonical SMILES |
COC1=C(C2=C(C=C1O)OC(=CC2=O)C3=CC=CC=C3)O
|
||||
InChI |
1S/C16H12O5/c1-20-16-11(18)8-13-14(15(16)19)10(17)7-12(21-13)9-5-3-2-4-6-9/h2-8,18-19H,1H3
|
||||
InChIKey |
LKOJGSWUMISDOF-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 480-11-5
|
||||
Herb ID | |||||
ETMC ID | |||||
SymMap ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
In-vivo Model | Murine hepatoma 22 (H22) cells were diluted with icy 0.9% saline and inoculated subcutaneously at right axilla of mice (5*106 viable cells/mL). | |||||
Experimental
Result(s) |
The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU and oroxylin A combinations were synergistic and oroxylin A increased the sensitivity of HepG2 cells to 5-FU by modulating the metabolic enzymes of 5-FU and apoptotic-related proteins. | |||||
β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | XPC | Molecule Info |
Pathway MAP
|
|
In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
PLA-801D | CVCL_7110 | Lung giant cell carcinoma | Homo sapiens | |||
PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | |||
HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1alpha mediated XPC transcription. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Apoptosis regulator Bcl-2 (BCL-2) | Molecule Info | [4] | |
Caspase-3 (CASP3) | Molecule Info | [5] | ||
Cyclin-dependent kinase 7 (CDK7) | Molecule Info | [6] | ||
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | p53 signaling pathway | |||
3 | Apoptosis | |||
4 | Natural killer cell mediated cytotoxicity | |||
5 | TNF signaling pathway | |||
6 | Serotonergic synapse | |||
7 | Non-alcoholic fatty liver disease (NAFLD) | |||
8 | Alzheimer's disease | |||
9 | Parkinson's disease | |||
10 | Amyotrophic lateral sclerosis (ALS) | |||
11 | Huntington's disease | |||
12 | Epithelial cell signaling in Helicobacter pylori infection | |||
13 | Pertussis | |||
14 | Legionellosis | |||
15 | Toxoplasmosis | |||
16 | Amoebiasis | |||
17 | Tuberculosis | |||
18 | Hepatitis B | |||
19 | Herpes simplex infection | |||
20 | Pathways in cancer | |||
21 | Viral carcinogenesis | |||
22 | Proteoglycans in cancer | |||
23 | MicroRNAs in cancer | |||
24 | Colorectal cancer | |||
25 | Viral myocarditis | |||
26 | NF-kappa B signaling pathway | |||
27 | HIF-1 signaling pathway | |||
28 | Sphingolipid signaling pathway | |||
29 | Protein processing in endoplasmic reticulum | |||
30 | PI3K-Akt signaling pathway | |||
31 | Adrenergic signaling in cardiomyocytes | |||
32 | Focal adhesion | |||
33 | Neurotrophin signaling pathway | |||
34 | Cholinergic synapse | |||
35 | Epstein-Barr virus infection | |||
36 | Prostate cancer | |||
37 | Small cell lung cancer | |||
38 | Basal transcription factors | |||
39 | Nucleotide excision repair | |||
40 | Cell cycle | |||
NetPath Pathway | TCR Signaling Pathway | Click to Show/Hide | ||
2 | IL2 Signaling Pathway | |||
3 | IL4 Signaling Pathway | |||
4 | IL5 Signaling Pathway | |||
5 | IL3 Signaling Pathway | |||
6 | Leptin Signaling Pathway | |||
7 | RANKL Signaling Pathway | |||
8 | TSLP Signaling Pathway | |||
Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
2 | FAS signaling pathway | |||
3 | Huntington disease | |||
4 | CCKR signaling map ST | |||
5 | Oxidative stress response | |||
Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
2 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
3 | FAS (CD95) signaling pathway | |||
4 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
5 | Posttranslational regulation of adherens junction stability and dissassembly | |||
6 | p75(NTR)-mediated signaling | |||
7 | HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||
8 | Caspase Cascade in Apoptosis | |||
9 | Syndecan-2-mediated signaling events | |||
10 | IL2-mediated signaling events | |||
11 | IL2 signaling events mediated by PI3K | |||
12 | Ceramide signaling pathway | |||
13 | Direct p53 effectors | |||
14 | RXR and RAR heterodimerization with other nuclear receptor | |||
15 | ATF-2 transcription factor network | |||
16 | C-MYB transcription factor network | |||
17 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
18 | EPO signaling pathway | |||
19 | IL2 signaling events mediated by STAT5 | |||
20 | Validated targets of C-MYC transcriptional repression | |||
21 | Retinoic acid receptors-mediated signaling | |||
Reactome | SMAC binds to IAPs | Click to Show/Hide | ||
2 | SMAC-mediated dissociation of IAP:caspase complexes | |||
3 | Apoptotic cleavage of cellular proteins | |||
4 | Degradation of the extracellular matrix | |||
5 | NADE modulates death signalling | |||
6 | Activation of DNA fragmentation factor | |||
7 | Caspase-mediated cleavage of cytoskeletal proteins | |||
8 | Activation of BAD and translocation to mitochondria | |||
9 | BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | |||
10 | The NLRP1 inflammasome | |||
11 | NoRC negatively regulates rRNA expression | |||
12 | Formation of TC-NER Pre-Incision Complex | |||
13 | Dual incision in TC-NER | |||
14 | Gap-filling DNA repair synthesis and ligation in TC-NER | |||
15 | Cyclin E associated events during G1/S transition | |||
16 | Cyclin D associated events in G1 | |||
17 | Cyclin A/B1 associated events during G2/M transition | |||
18 | Cyclin A:Cdk2-associated events at S phase entry | |||
19 | RNA Polymerase I Transcription Initiation | |||
WikiPathways | DNA Damage Response | Click to Show/Hide | ||
2 | SIDS Susceptibility Pathways | |||
3 | Apoptosis Modulation by HSP70 | |||
4 | MAPK Signaling Pathway | |||
5 | Copper homeostasis | |||
6 | FAS pathway and Stress induction of HSP regulation | |||
7 | Signaling by Hippo | |||
8 | Apoptosis | |||
9 | Amyotrophic lateral sclerosis (ALS) | |||
10 | Spinal Cord Injury | |||
11 | BDNF signaling pathway | |||
12 | Integrated Pancreatic Cancer Pathway | |||
13 | Oncostatin M Signaling Pathway | |||
14 | Parkinsons Disease Pathway | |||
15 | Corticotropin-releasing hormone | |||
16 | Allograft Rejection | |||
17 | AGE/RAGE pathway | |||
18 | TNF alpha Signaling Pathway | |||
19 | Prostate Cancer | |||
20 | Alzheimers Disease | |||
21 | TWEAK Signaling Pathway | |||
22 | Integrated Breast Cancer Pathway | |||
23 | Signalling by NGF | |||
24 | Integrated Cancer pathway | |||
25 | Regulation of Apoptosis | |||
26 | Intrinsic Pathway for Apoptosis | |||
27 | Apoptotic execution phase | |||
28 | Apoptosis Modulation and Signaling | |||
29 | miRNA Regulation of DNA Damage Response | |||
30 | DNA Damage Response (only ATM dependent) | |||
31 | Senescence and Autophagy in Cancer | |||
32 | IL-2 Signaling Pathway | |||
33 | Focal Adhesion | |||
34 | Kit receptor signaling pathway | |||
35 | IL-3 Signaling Pathway | |||
36 | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
37 | Nanoparticle triggered autophagic cell death | |||
38 | Interleukin-11 Signaling Pathway | |||
39 | miR-targeted genes in muscle cell - TarBase | |||
40 | miR-targeted genes in lymphocytes - TarBase | |||
41 | miR-targeted genes in leukocytes - TarBase | |||
42 | TP53 Network | |||
43 | Influenza A virus infection | |||
44 | IL-5 Signaling Pathway | |||
45 | G1 to S cell cycle control | |||
46 | Eukaryotic Transcription Initiation | |||
47 | Cardiac Hypertrophic Response | |||
48 | S Phase | |||
49 | HIV Life Cycle | |||
50 | Nucleotide Excision Repair | |||
51 | RNA Polymerase II Transcription | |||
52 | RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | |||
53 | mRNA Capping | |||
54 | Mitotic G2-G2/M phases | |||
55 | Mitotic G1-G1/S phases | |||
56 | MicroRNAs in cardiomyocyte hypertrophy |




